Optimizing the Yield of Recombinant Pharmaceutical Proteins in Plants
Richard M. Twyman,
The production of recombinant pharmaceutical proteins in plants is entering a new phase with the recent approval of recombinant
glucocerebrosidase produced in carrot cells and the successful production of clinical-grade proteins in diverse plant-based production
platforms. In the long journey from concept to product, the field of molecular farming has faced technical and economic hurdles,
many reflecting the initially limited productivity of plants compared to established platforms such as mammalian cells. This challenge
has been met by innovative research aiming to increase recombinant protein yields and maximize the economic benefits of plants. Research
has focused on increasing the intrinsic yield capability of plants by optimizing expression construct design, and also on novel
strategies to avoid epigenetic silencing and environmental effects on protein accumulation. In this article, we discuss the diverse approaches
that have been used to increase the productivity of plant-based platforms for the production of recombinant pharmaceutical proteins
and consider future opportunities to maximize the potential of plants and increase their competitiveness outside niche markets.
Keywords: Molecular farming, yield optimization, transgene expression, promoter, protein stability.
Rights & PermissionsPrintExport